A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma

被引：0
|
作者：
Peter J Hosein
Jessica Macintyre
Carolina Kawamura
Jennifer Cudris Maldonado
Vinicius Ernani
Arturo Loaiza-Bonilla
Govindarajan Narayanan
Afonso Ribeiro
Lorraine Portelance
Jaime R Merchan
Joe U Levi
Caio M Rocha-Lima
机构：
[1] University of Miami/Sylvester Comprehensive Cancer Center,Department of Medicine, Division of Hematology/Oncology
[2] University of Miami/Sylvester Comprehensive Cancer Center,Institution: Department of Medicine, Division of Hematology/Oncology
[3] Advanced Oncology Center of Hospital São José,Department of Medicine, Division of Hematology/Oncology
[4] University of Miami/Sylvester Comprehensive Cancer Center,Department of Medicine
[5] University of Miami/Sylvester Comprehensive Cancer Center,Department of Medicine, Division of Hematology/Oncology
[6] University of Miami/Sylvester Comprehensive Cancer Center,Department of Radiology
[7] University of Miami/Sylvester Comprehensive Cancer Center,Department of Medicine, Division of Gastroenterology
[8] University of Miami/Sylvester Comprehensive Cancer Center,Department of Radiation Oncology
[9] University of Miami/Sylvester Comprehensive Cancer Center,Department of Medicine, Division of Hematology/Oncology
[10] University of Miami/Sylvester Comprehensive Cancer Center,Department of Surgery
[11] University of Miami/Sylvester Comprehensive Cancer Center,Department of Medicine, Division of Hematology/Oncology
[12] University of Miami/Sylvester Comprehensive Cancer Center,undefined
来源：
BMC Cancer | / 12卷
关键词：
Pancreatic ductal carcinoma; neoadjuvant therapy; surgery; radiation therapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma
    Hosein, Peter J.
    Macintyre, Jessica
    Kawamura, Carolina
    Maldonado, Jennifer Cudris
    Ernani, Vinicius
    Loaiza-Bonilla, Arturo
    Narayanan, Govindarajan
    Ribeiro, Afonso
    Portelance, Lorraine
    Merchan, Jaime R.
    Levi, Joe U.
    Rocha-Lima, Caio M.
    BMC CANCER, 2012, 12
  • [2] FOLFIRINOX in borderline resectable and locally advanced unresectable pancreatic adenocarcinoma
    Yoo, Changhoon
    Hwang, Inhwan
    Song, Tae Jun
    Lee, Sang Soo
    Jeong, Jae Ho
    Park, Do Hyun
    Seo, Dong Wan
    Lee, Sung Koo
    Kim, Myung-Hwan
    Byun, Jae Ho
    Park, Jin-hong
    Hwang, Dae Wook
    Song, Ki Byung
    Lee, Jae Hoon
    Lee, Woohyung
    Chang, Heung-Moon
    Kim, Kyu-pyo
    Kim, Song Cheol
    Ryoo, Baek-Yeol
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2020, 12
  • [3] Neo-adjuvant FOLFIRINOX in borderline-resectable/locally advanced pancreatic adenocarcinoma
    Temraz, S.
    Albonji, W.
    Charafeddine, M.
    Farhat, Z.
    Mukherji, D.
    Shamseddine, A.
    ANNALS OF ONCOLOGY, 2016, 27 : 95 - 95
  • [4] Neo-adjuvant FOLFIRINOX in borderline-resectable/locally advanced pancreatic adenocarcinoma: An updated analysis
    Temraz, S.
    Hammoud, M. Salim
    Zorkot, M.
    Albonji, W.
    Dbouk, H.
    Farhat, F.
    Charafeddine, M.
    Mukherji, D.
    Shamseddine, A.
    ANNALS OF ONCOLOGY, 2018, 29
  • [5] Prospective efficacy and safety study of neoadjuvant gemcitabine with capecitabine combination chemotherapy for borderline-resectable or unresectable locally advanced pancreatic adenocarcinoma
    Lee, Jae-Lyun
    Kim, Song Cheol
    Kim, Ji-Hoon
    Lee, Sang Soo
    Kim, Tae-Won
    Park, Do Hyun
    Seo, Dong Wan
    Lee, Sung Koo
    Kim, Myung-Hwan
    Kim, Jong Hoon
    Park, Jin-Hong
    Shin, Sang Hyun
    Han, Duck Jong
    SURGERY, 2012, 152 (05) : 851 - 862
  • [6] Neoadjuvant FOLFIRINOX Application in Borderline Resectable Pancreatic Adenocarcinoma A Retrospective Cohort Study
    Paniccia, Alessandro
    Edil, Barish H.
    Schulick, Richard D.
    Byers, Joshua T.
    Meguid, Cheryl
    Gajdos, Csaba
    McCarter, Martin D.
    MEDICINE, 2014, 93 (27)
  • [7] Neoadjuvant Modified (m) FOLFIRINOX for Locally Advanced Unresectable (LAPC) and Borderline Resectable (BRPC) Adenocarcinoma of the Pancreas
    Blazer, Marlo
    Wu, Christina
    Goldberg, Richard M.
    Phillips, Gary
    Schmidt, Carl
    Muscarella, Peter
    Wuthrick, Evan
    Williams, Terrence M.
    Reardon, Joshua
    Ellison, E. Christopher
    Bloomston, Mark
    Bekaii-Saab, Tanios
    ANNALS OF SURGICAL ONCOLOGY, 2015, 22 (04) : 1153 - 1159
  • [8] Neoadjuvant Modified (m) FOLFIRINOX for Locally Advanced Unresectable (LAPC) and Borderline Resectable (BRPC) Adenocarcinoma of the Pancreas
    Marlo Blazer
    Christina Wu
    Richard M. Goldberg
    Gary Phillips
    Carl Schmidt
    Peter Muscarella
    Evan Wuthrick
    Terrence M. Williams
    Joshua Reardon
    E. Christopher Ellison
    Mark Bloomston
    Tanios Bekaii-Saab
    Annals of Surgical Oncology, 2015, 22 : 1153 - 1159
  • [9] Neoadjuvant Nab-paclitaxel and Gemcitabine in Borderline Resectable or Locally Advanced Unresectable Pancreatic Adenocarcinoma in Patients Who Are Ineligible for FOLFIRINOX
    Peterson, Shawn L.
    Husnain, Muhammad
    Pollack, Terri
    Pimentel, Agustin
    Loaiza-Bonilla, Arturo
    Westendorf-Overley, Colleen
    Ratermann, Kelley
    Anthony, Lowell
    Desimone, Philip
    Goel, Gaurav
    Kudrimoti, Mahesh
    Dineen, Sean
    Tzeng, Ching-Wei D.
    Hosein, Peter J.
    ANTICANCER RESEARCH, 2018, 38 (07) : 4035 - 4039
  • [10] Tolerability and efficacy of modified FOLFIRINOX (mFOLFIRINOX) in patients with borderline-resectable pancreatic cancer (BRPC) and locally advanced unresectable pancreatic cancer (LAURPC)
    Blazer, Marlo A.
    Wu, Christina Sing-Ying
    Goldberg, Richard M.
    Phillips, Gary S.
    Schmidt, Carl Richard
    Muscarella, Peter
    El-Dika, Samer S.
    Walker, Jon P.
    Krishna, Somashekar Gopala
    Groce, J. Royce
    Wuthrick, Evan John
    Williams, Terence M.
    Efries, David
    Smith, Yahna T.
    Mathey, Kris
    Wagner, Mandy
    Reardon, Josh
    Ellison, Edwin Christopher
    Bloomston, Mark
    Bekaii-Saab, Tanios S.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
12345